La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

InspireMD Crescita futura

Future criteri di controllo 2/6

Si prevede che InspireMD aumenterà i ricavi a una percentuale annua pari a 59.5%.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	17.7%
Tasso di crescita dei ricavi	59.5%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	06 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation

Jan 11

Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares

Feb 11

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:NSPR - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	30	N/A	N/A	N/A	1
12/31/2025	10	N/A	N/A	N/A	1
12/31/2024	7	N/A	N/A	N/A	1
6/30/2024	7	-26	-19	-18	N/A
3/31/2024	6	-23	-17	-17	N/A
12/31/2023	6	-20	-17	-16	N/A
9/30/2023	5	-19	-16	-15	N/A
6/30/2023	5	-19	-17	-16	N/A
3/31/2023	5	-18	-17	-16	N/A
12/31/2022	5	-18	-16	-16	N/A
9/30/2022	6	-18	-16	-15	N/A
6/30/2022	5	-17	-15	-14	N/A
3/31/2022	5	-16	-14	-14	N/A
12/31/2021	4	-15	-14	-13	N/A
9/30/2021	3	-15	-13	-13	N/A
6/30/2021	3	-13	-12	-11	N/A
3/31/2021	2	-12	-10	-10	N/A
12/31/2020	2	-11	-9	-9	N/A
9/30/2020	3	-9	-9	-8	N/A
6/30/2020	3	-9	-7	-7	N/A
3/31/2020	4	-9	-9	-9	N/A
12/31/2019	4	-10	-10	-10	N/A
9/30/2019	4	-10	-10	-10	N/A
6/30/2019	3	-10	-10	-10	N/A
3/31/2019	3	-8	-9	-9	N/A
12/31/2018	4	-8	-8	-8	N/A
9/30/2018	4	-11	-8	-8	N/A
6/30/2018	4	-11	-8	-8	N/A
3/31/2018	3	-12	N/A	-7	N/A
12/31/2017	3	-13	N/A	-8	N/A
9/30/2017	2	-10	N/A	-8	N/A
6/30/2017	2	-10	N/A	-9	N/A
3/31/2017	2	-9	N/A	-8	N/A
12/31/2016	2	-8	N/A	-7	N/A
9/30/2016	2	-9	N/A	-8	N/A
6/30/2016	2	-11	N/A	-7	N/A
3/31/2016	2	-13	N/A	-9	N/A
12/31/2015	2	-16	N/A	-12	N/A
9/30/2015	3	-18	N/A	-14	N/A
6/30/2015	2	-21	N/A	-18	N/A
3/31/2015	2	-24	N/A	-20	N/A
12/31/2014	3	-25	N/A	-19	N/A
9/30/2014	4	-26	N/A	-18	N/A
6/30/2014	5	-23	N/A	-15	N/A
3/31/2014	6	-30	N/A	-12	N/A
12/31/2013	6	-29	N/A	-11	N/A
9/30/2013	6	-26	N/A	-11	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista NSPR è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di NSPR cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di NSPR cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di NSPR ( 59.5% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di NSPR ( 59.5% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di NSPR è previsto essere elevato tra 3 anni

InspireMD Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates decrease by 12%, EPS upgraded

Consensus EPS estimates fall by 13%

Price target increased by 18% to US$4.85

Consensus EPS estimates upgraded to US$0.77 loss

Price target increased by 12% to US$4.35

Consensus estimates of losses per share improve by 46%

Recent updates

Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023)

New minor risk - Share price stability

InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Independent Director exercised options to buy US$153k worth of stock.

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023)

InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation

Insider recently bought US$127k worth of stock

Consensus EPS estimates fall by 13%

Price target increased by 18% to US$4.85

Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical Trial

InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023

InspireMD, Inc. Announces Management Appointments

Consensus EPS estimates upgraded to US$0.77 loss

Price target increased by 12% to US$4.35

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023

InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial

Consensus estimates of losses per share improve by 46%

InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investors

InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023

Consensus revenue estimates decrease by 37%, EPS upgraded

Price target decreased to US$5.60

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insider recently bought US$68k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

InspireMD, Inc. to Report Q2, 2022 Results on Aug 09, 2022

InspireMD, Inc. Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

InspireMD, Inc., Annual General Meeting, Aug 31, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$9.00

Full year 2021 earnings: EPS misses analyst expectations

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

InspireMD, Inc. to Report Q4, 2021 Results on Mar 08, 2022

InspireMD Appoints Adnan Siddiqui as Member of Its Scientific Advisory Board and Strategic Advisor

We Think InspireMD (NASDAQ:NSPR) Needs To Drive Business Growth Carefully

Insider recently bought US$50k worth of stock

Insider recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020)

We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate

InspireMD: Revolutionizing The Field Of Vascular Stenting

Insider recently bought US$93k worth of stock

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020)

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020)

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019)

Earnings beat expectations, revenue disappoints

InspireMD, Inc. to Report Q4, 2020 Results on Mar 09, 2021

InspireMD, Inc. Engages Hart Clinical Consultants to Conduct Clinical Trial for Cguard Carotid Stent System in the United States

Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares

InspireMD, Inc. Appoints Chris Metzger as Principal Investigator for CGuard Registration Trial in the United States

New 90-day high: US$0.82

InspireMD, Inc. has completed a Composite Units Offering in the amount of $18 million.

InspireMD, Inc. Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

New 90-day high: US$0.71

New 90-day high: US$0.44

Analysts update estimates

Third quarter 2020 earnings released: US$0.064 loss per share

Revenue beats expectations, earnings disappoint

Inspiremd, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing

InspireMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020